Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis

BACKGROUND: In the clinical use of third-line treatment of non-Hodgkin lymphoma (NHL), the combination treatment is increasingly used due to problems such as drug resistance, and while their efficacy has been proven, whether they are economical has become a new issue. A recent trial showed copanlisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiao, Chen, Xudong, Zhang, Tiantian, Jiang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011241/
https://www.ncbi.nlm.nih.gov/pubmed/35433977
http://dx.doi.org/10.21037/atm-22-1159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011241/
https://www.ncbi.nlm.nih.gov/pubmed/35433977
http://dx.doi.org/10.21037/atm-22-1159

Ejemplares similares